154 related articles for article (PubMed ID: 18304966)
1. Optimisation of circulating biomarkers of cell death for routine clinical use.
Greystoke A; Cummings J; Ward T; Simpson K; Renehan A; Butt F; Moore D; Gietema J; Blackhall F; Ranson M; Hughes A; Dive C
Ann Oncol; 2008 May; 19(5):990-5. PubMed ID: 18304966
[TBL] [Abstract][Full Text] [Related]
2. Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
Cummings J; Ranson M; Lacasse E; Ganganagari JR; St-Jean M; Jayson G; Durkin J; Dive C
Br J Cancer; 2006 Jul; 95(1):42-8. PubMed ID: 16804528
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.
de Haas EC; di Pietro A; Simpson KL; Meijer C; Suurmeijer AJ; Lancashire LJ; Cummings J; de Jong S; de Vries EG; Dive C; Gietema JA
Neoplasia; 2008 Oct; 10(10):1041-8. PubMed ID: 18813353
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.
Ozturk B; Coskun U; Sancak B; Yaman E; Buyukberber S; Benekli M
Int Immunopharmacol; 2009 May; 9(5):645-8. PubMed ID: 19249390
[TBL] [Abstract][Full Text] [Related]
5. M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC.
Chu T; Jiang L; Ying W; Han B
Clin Transl Oncol; 2017 Mar; 19(3):326-331. PubMed ID: 27468866
[TBL] [Abstract][Full Text] [Related]
6. Serum cytokeratin 18 as a biomarker for gastric cancer.
Oyama K; Fushida S; Kinoshita J; Okamoto K; Makino I; Nakamura K; Hayashi H; Inokuchi M; Nakagawara H; Tajima H; Fujita H; Takamura H; Ninomiya I; Kitagawa H; Fujimura T; Ohta T
Clin Exp Med; 2013 Nov; 13(4):289-95. PubMed ID: 22825587
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of serum M30 and M65 levels in melanoma.
Tas F; Karabulut S; Serilmez M; Yildiz I; Sen F; Ciftci R; Duranyildiz D
Melanoma Res; 2013 Oct; 23(5):390-5. PubMed ID: 23812330
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma.
Sen F; Yildiz I; Odabas H; Tambas M; Kilic L; Karadeniz A; Altun M; Ekenel M; Serilmez M; Duranyildiz D; Bavbek S; Basaran M
Tumour Biol; 2015 Feb; 36(2):1039-44. PubMed ID: 25326440
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity.
Cummings J; Hodgkinson C; Odedra R; Sini P; Heaton SP; Mundt KE; Ward TH; Wilkinson RW; Growcott J; Hughes A; Dive C
Mol Cancer Ther; 2008 Mar; 7(3):455-63. PubMed ID: 18347133
[TBL] [Abstract][Full Text] [Related]
10. Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
Linder S; Olofsson MH; Herrmann R; Ulukaya E
Expert Rev Mol Diagn; 2010 Apr; 10(3):353-9. PubMed ID: 20370591
[TBL] [Abstract][Full Text] [Related]
11. Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?
Bilici A; Ustaalioglu BB; Ercan S; Orcun A; Seker M; Salepci T; Gumus M
Cancer Chemother Pharmacol; 2011 Aug; 68(2):309-16. PubMed ID: 20967544
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma.
Tas F; Karabulut S; Bilgin E; Sen F; Yildiz I; Tastekin D; Ciftci R; Duranyildiz D
Tumour Biol; 2013 Dec; 34(6):3529-36. PubMed ID: 23784459
[TBL] [Abstract][Full Text] [Related]
13. Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma.
Cummings J; Ranson M; Butt F; Moore D; Dive C
Cancer Chemother Pharmacol; 2007 Nov; 60(6):921-4. PubMed ID: 17333190
[TBL] [Abstract][Full Text] [Related]
14. Elevated serum levels of cell death circulating biomarkers, M30 and M65, in patients with β-thalassemia major.
Esmaeil N; Moayedi B; Gharagozloo M; Maracy MR
Hemoglobin; 2013; 37(4):404-10. PubMed ID: 23600495
[TBL] [Abstract][Full Text] [Related]
15. The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer.
Ustaalioglu BB; Bilici A; Ercan S; Seker M; Orcun A; Gumus M
Med Oncol; 2013 Jun; 30(2):551. PubMed ID: 23536001
[TBL] [Abstract][Full Text] [Related]
16. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers.
Shen J; Chan HL; Wong GL; Chan AW; Choi PC; Chan HY; Chim AM; Yeung DK; Yu J; Chu WC; Wong VW
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1057-66. PubMed ID: 23066946
[TBL] [Abstract][Full Text] [Related]
17. Application of the β-expectation tolerance interval to method validation of the M30 and M65 ELISA cell death biomarker assays.
Cummings J; Zhou C; Dive C
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Apr; 879(13-14):887-93. PubMed ID: 21450541
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of serum M30 and M65 levels in patients with breast cancer.
Tas F; Karabulut S; Yildiz I; Duranyildiz D
Biomed Pharmacother; 2014 Oct; 68(8):1135-40. PubMed ID: 25465151
[TBL] [Abstract][Full Text] [Related]
19. Caspase-cleaved keratin-18 fragments increase during alcohol withdrawal and predict liver-related death in patients with alcoholic liver disease.
Mueller S; Nahon P; Rausch V; Peccerella T; Silva I; Yagmur E; Straub BK; Lackner C; Seitz HK; Rufat P; Sutton A; Bantel H; Longerich T
Hepatology; 2017 Jul; 66(1):96-107. PubMed ID: 28170108
[TBL] [Abstract][Full Text] [Related]
20. Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls.
Oven Ustaalioglu B; Bilici A; Ercan S; Orcun A; Seker M; Ozkan A; Ustaalioglu R; Gumus M
Clin Transl Oncol; 2012 May; 14(5):356-61. PubMed ID: 22551541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]